期刊文献+

Development of a New High-throughput Screening Model for Human High Density Lipoprotein Receptor (CLA-1) Agonists 被引量:1

Development of a New High-throughput Screening Model for Human High Density Lipoprotein Receptor (CLA-1) Agonists
下载PDF
导出
摘要 To develop a new high-throughput screening model for human high-density lipoprotein (HDL) receptor (CD36 and LIMPⅡ analogous-1, CLA-1) agonists using CLA-1-expressing insect cells. Methods With the total RNA of human hepatoma cells BEL-7402 as template, the complementary DNA (cDNA) of CLA-1 was amplified by reverse transcription-polymerase chain reaction (RT-PCR). Bac-to-Bac baculovirus expression system was used to express CLA-1 in insect cells. CLA-1 cDNA was cloned downstream of polyhedrin promoter of Autographa californica nuclear polyhedrosis virus (AcNPV) into donor vector pFastBacl and recombinant pFastBacl-CLA-1 was transformed into E. coli DH10Bac to transpose CLA-1 cDNA to bacrnid DNA. Recombinant bacrnid-CLA-1 was transfected into Spodopterafrugiperda Sf9 insect cells to produce recombinant baculovirus particles. Recombinant CLA- 1 was expressed on the membrane of Sf9 cells infected with the recombinant baculoviruses. A series of parameters of DiI-lipoprotein binding assays of CLA-1-expressing Sf9 cells in 96-well plates were optimized. Results Western blot analysis and DiI-lipoprotein binding assays confirmed that CLA-1 expressed in insect cells had similar immunoreactivity and ligand binding activity as its native counterpart. A reliable and sensitive in vitro cell-based assay was established to assess the activity of CLA-1 and used to screen agonists from different sample libraries. Conclusion Human HDL receptor CLA-1 was successfully expressed in Sf9 insect cells and a novel high-throughput screening model for CLA-1 agonists was developed. Utilization of this model allows us to identify potent and selective CLA-1 agonists which might possibly be used as therapeutics for atherosclerosis. To develop a new high-throughput screening model for human high-density lipoprotein (HDL) receptor (CD36 and LIMPⅡ analogous-1, CLA-1) agonists using CLA-1-expressing insect cells. Methods With the total RNA of human hepatoma cells BEL-7402 as template, the complementary DNA (cDNA) of CLA-1 was amplified by reverse transcription-polymerase chain reaction (RT-PCR). Bac-to-Bac baculovirus expression system was used to express CLA-1 in insect cells. CLA-1 cDNA was cloned downstream of polyhedrin promoter of Autographa californica nuclear polyhedrosis virus (AcNPV) into donor vector pFastBacl and recombinant pFastBacl-CLA-1 was transformed into E. coli DH10Bac to transpose CLA-1 cDNA to bacrnid DNA. Recombinant bacrnid-CLA-1 was transfected into Spodopterafrugiperda Sf9 insect cells to produce recombinant baculovirus particles. Recombinant CLA- 1 was expressed on the membrane of Sf9 cells infected with the recombinant baculoviruses. A series of parameters of DiI-lipoprotein binding assays of CLA-1-expressing Sf9 cells in 96-well plates were optimized. Results Western blot analysis and DiI-lipoprotein binding assays confirmed that CLA-1 expressed in insect cells had similar immunoreactivity and ligand binding activity as its native counterpart. A reliable and sensitive in vitro cell-based assay was established to assess the activity of CLA-1 and used to screen agonists from different sample libraries. Conclusion Human HDL receptor CLA-1 was successfully expressed in Sf9 insect cells and a novel high-throughput screening model for CLA-1 agonists was developed. Utilization of this model allows us to identify potent and selective CLA-1 agonists which might possibly be used as therapeutics for atherosclerosis.
出处 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2005年第4期265-272,共8页 生物医学与环境科学(英文版)
基金 ThisworkwassupportedbytheNationalNaturalScienceFoundationofChina(GrantNo.39930190)andMega-projectsofScienceResearchforthe10thFive-YearPlan(GrantNo.2004AA2Z3784).
关键词 HDL SR-BI CLA-1 Insect cells High-throughput screening model AGONIST HDL SR-BI CLA-1 Insect cells High-throughput screening model Agonist
  • 相关文献

参考文献22

  • 1Kwiterovich, P. O. (1998). The antiatherogenic role of highdensity lipoprotein cholesterol. Am. J. Cardiol. 82(9A),13Q-21Q. 被引量:1
  • 2Tall, A. R. (1990). Plasma high density lipoproteins.Metabolism and relationship to atherogenesis. J. Clin. Invest.86(2), 379-384. 被引量:1
  • 3Shah, P. K. (2003). Emerging non-Statin LDL-lowering therapies for dyslipidemia and atheroselerosis. Rev. Cardiovasc.Med. 4(3), 136-141. 被引量:1
  • 4Barter, P. J. and Rye, K. A. (1996). High density lipoproteins and coronary heart disease. Atherosclerosis 121(1), 1-12. 被引量:1
  • 5Gordon, D. J. and Rifkind, B. M. (1989). High-density lipoprotein-the clinical implications of recent studies. New Engl.J. Med. 321(19), 1311-1316. 被引量:1
  • 6Price, M. J. and Shah, P. K. (2002). New Strategies in managing and preventing atheroselerosis: focus on HDL. Rev. Cardiovasc.Med. 3(3), 129-137. 被引量:1
  • 7Andersen, J. M. and Dietschy, J. M. (1981). Kinetic parameters of the lipoprotein transport systems in the adrenal gland of the rat determined in vivo. Comparison of low and high density lipoproteins of human and rat origin. J. BioL Chem. 256(14),7362-7370. 被引量:1
  • 8Krieger, M. (1999). Charting the fate of the "good cholesterol":identification and characterization of the HDL receptor SR-BI.Annu. Rev. Biochem. 68(3), 523-558. 被引量:1
  • 9Fielding, C. J. arid Fielding, P. E. (1995). Molecular physiology of reverse cholesterol transport. J. Lipid. Res. 36(2), 211-228. 被引量:1
  • 10Johnson, W. J., Mahlberg, F. H., Rothblat, G. H., and Phillips,M. C. (1991). Cholesterol transport between cells and high-density lipoproteins. Biochim. Biophys. Acta. 1085(3),273-298. 被引量:1

同被引文献4

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部